Quick Heal Technologies（539678）株式概要クイック・ヒール・テクノロジーズ社は、インド内外の消費者、中小企業、政府機関、企業向けにセキュリティ・ソフトウェア製品とソリューションの提供を行っている。 詳細539678 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析過去5年間で収益は年間49.8%減少しました。 Indian市場と比較して、過去 3 か月間の株価の変動が非常に大きい財務結果に影響を与える大きな一時的項目 利益率(2.1%)は昨年より低い(7.6%) すべてのリスクチェックを見る539678 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₹Current Price₹198.20142.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture04b2016201920222025202620282031Revenue ₹2.3bEarnings ₹46.7mAdvancedSet Fair ValueView all narrativesQuick Heal Technologies Limited 競合他社TAC InfosecSymbol: NSEI:TACMarket cap: ₹8.2bRamco SystemsSymbol: NSEI:RAMCOSYSMarket cap: ₹17.6bABM KnowledgewareSymbol: BSE:531161Market cap: ₹4.7b3i InfotechSymbol: NSEI:3IINFOLTDMarket cap: ₹3.6b価格と性能株価の高値、安値、推移の概要Quick Heal Technologies過去の株価現在の株価₹198.2052週高値₹416.0052週安値₹125.00ベータ0.0951ヶ月の変化15.20%3ヶ月変化10.79%1年変化-31.25%3年間の変化42.33%5年間の変化-11.48%IPOからの変化-22.11%最新ニュースNew Risk • May 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin).New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026Reported Earnings • Oct 19Second quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.77 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.43 (up from ₹0.77 in 2Q 2025). Revenue: ₹879.0m (up 20% from 2Q 2025). Net income: ₹79.1m (up 91% from 2Q 2025). Profit margin: 9.0% (up from 5.6% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.最新情報をもっと見るRecent updatesNew Risk • May 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin).New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026Reported Earnings • Oct 19Second quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.77 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.43 (up from ₹0.77 in 2Q 2025). Revenue: ₹879.0m (up 20% from 2Q 2025). Net income: ₹79.1m (up 91% from 2Q 2025). Profit margin: 9.0% (up from 5.6% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.お知らせ • Sep 02+ 2 more updatesQuick Heal Technologies Limited to Report Q3, 2026 Results on Feb 14, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results on Feb 14, 2026お知らせ • Sep 01Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.Reported Earnings • Aug 08First quarter 2026 earnings released: ₹1.00 loss per share (vs ₹0.75 profit in 1Q 2025)First quarter 2026 results: ₹1.00 loss per share (down from ₹0.75 profit in 1Q 2025). Revenue: ₹629.8m (down 10% from 1Q 2025). Net loss: ₹55.1m (down 237% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.お知らせ • Aug 02Quick Heal Technologies Limited to Report Q1, 2026 Results on Aug 07, 2025Quick Heal Technologies Limited announced that they will report Q1, 2026 results on Aug 07, 2025New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.8% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin).Reported Earnings • May 10Full year 2025 earnings released: EPS: ₹0.94 (vs ₹4.56 in FY 2024)Full year 2025 results: EPS: ₹0.94 (down from ₹4.56 in FY 2024). Revenue: ₹3.00b (up 2.9% from FY 2024). Net income: ₹50.4m (down 79% from FY 2024). Profit margin: 1.7% (down from 8.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.お知らせ • May 01Quick Heal Technologies Limited to Report Q4, 2025 Results on May 06, 2025Quick Heal Technologies Limited announced that they will report Q4, 2025 results on May 06, 2025お知らせ • Apr 01Quick Heal Technologies Limited Announces Resignation of Shailesh Lakhani as DirectorQuick Heal Technologies Limited announced resignation of Mr. Shailesh Lakhani as Director with effect from 31 March 2025.Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹297, the stock trades at a trailing P/E ratio of 71.5x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 74% over the past three years.Reported Earnings • Feb 05Third quarter 2025 earnings released: EPS: ₹0.02 (vs ₹1.89 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.02 (down from ₹1.89 in 3Q 2024). Revenue: ₹755.2m (down 7.8% from 3Q 2024). Net income: ₹1.10m (down 99% from 3Q 2024). Profit margin: 0.1% (down from 12% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.お知らせ • Jan 29Quick Heal Technologies Limited to Report Q3, 2025 Results on Feb 04, 2025Quick Heal Technologies Limited announced that they will report Q3, 2025 results at 12:08 PM, Indian Standard Time on Feb 04, 2025Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹469, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 37x in the Software industry in India. Total returns to shareholders of 135% over the past three years.お知らせ • Dec 04Quick Heal Technologies Limited Launches Seqrite Malware Analysis Platform and Threat Intel SolutionQuick Heal Technologies Limited announced that the company announce the launch of its new product on 4 December, 2024 and issue of India Cyber Threat Report 2025. The product named Seqrite Malware Analysis Platform (SMAP) and Threat Intel Solution is set to launch on 4 December 2024. It falls under the category of Enterprise Security Software, specifically designed as a Malware Analysis Platform and Threat Intel Solution. This product will cater to the domestic market initially, with the first phase being introduced in the Domestic Market and plans to subsequently expand into other geographies.New Risk • Nov 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹19m sold).Reported Earnings • Oct 18Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹2.43 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.77 (down from ₹2.43 in 2Q 2024). Revenue: ₹786.9m (flat on 2Q 2024). Net income: ₹41.5m (down 68% from 2Q 2024). Profit margin: 5.3% (down from 17% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.お知らせ • Oct 11Quick Heal Technologies Limited to Report Q2, 2025 Results on Oct 17, 2024Quick Heal Technologies Limited announced that they will report Q2, 2025 results on Oct 17, 2024お知らせ • Oct 04Quick Heal Technologies Limited Announces the Launch of India's First Fraud Prevention Solution - AntiFraud.AIQuick Heal Technologies Limited announced the launch of India's first fraud prevention solution - AntiFraud.AI. This 'Made in India' solution opens a whole new category revolutionizing digital safety against the escalating threat of financial frauds which is impacting everyone including the most tech-savvy. The launch of AntiFraud.AI comes at a crucial time when financial fraud has reached alarming levels. According to the Indian Cybercrime Coordination Centre, the approximate amount that Indians lost to fraudsters between January to April 2024 stood at 1750 crores. The gravity of the situation is further underlined by the National Cybercrime Reporting Portal, suffered losses were reported through over 740,000 complaints. These staggering figures highlight the urgent need for comprehensive fraud prevention solutions, a need that Quick Heal's AntiFraud.AI aims to address head-on. AntiFraud.AI boasts a wide range of robust features designed to enhance user security and safeguard sensitive information. Key Features Include: 1. Risk Profile - Assess risk level with actionable recommendations to reduce exposure to fraud. 2. Fraud Call Alert - Alerts on receiving a potentially fraudulent call. 3. Scam Protection - Employs sophisticated algorithms to identify and block phishing links and fraudulent websites, enhancing online security. 4. Banking Fraud Alert - Utilizes artificial intelligence to detect and alert users to potential banking fraud attempts in real-time. 5. Fraud Protect Buddy - Empowers users to safeguard their loved ones by sharing alerts and security tips, specifically addressing the vulnerabilities of less tech-savvy individuals. 6. Fraud App Detector - Continuously scans for malicious applications and delivers real-time alerts about potentially harmful apps. 7. Secure Payments - Ensures a safe environment for online transactions and monitors for suspicious activity throughout the payment process. Unauthorized Access Alert - Notifies users if their device's microphone or camera is activated without consent, protecting against covert surveillance. Dark Web Monitoring - Actively scans the dark web for compromised sensitive data and provides timely notifications if users' information is found. . Call Forwarding Alert - Alerts when calls are being redirected without consent, The solution also offers Screen share alert, Payee Name Announcer, Spy Alert, File Vault and Browsing Protection and more. In addition to these, The Information Hub feature provides access to in-depth research and fraud intelligence from Seqrite Labs, India's largest malware analysis facility, keeping users informed about evolving threats with the latest fraud trends and prevention tips. This feature allows users to access Quick Heal's extensive domain expertise and knowledge. Furthermore, the Victim Support feature offers step- by-step guidance for those who fall victim to fraud, aiding in recovery and necessary actions. Together, these elements create a robust defense against fraud and enhance overall digital security.Board Change • Oct 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Kamal Agarwal was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Sep 09Quick Heal Technologies Limited Appoints Kamal Kumar Agarwal as an Independent DirectorQuick Heal Technologies Limited approved the appointment of Mr. Kamal Kumar Agarwal as an Independent Director of the company for a first term of five years commencing from July 26, 2024 at the AGM held on September 06, 2024. Mr. Kamal Kumar Agarwal 43, is a graduate in Bachelor of Commerce in year 2001. He is a Member of the Institute of Chartered Accountants of India. Part of CFO 100 2013 and 2016 Honor list under 'Winning Edge in a Finance Start-up. Mr. Kamal Kumar Agarwal, serving /served as Non-Executive Director & Investor Advisor for M/s NewCold, MN Bio-Technology, Giant Connection & a few. Mr. Kamal Kumar Agarwal has served as Group CFO - Indian Subcontinent & Director at Ferrero India Private Limited. He was also worked with blue chip companies Cadbury India Private Limited, ITC Limited and Tata Teleservices Limited. Currently incubating two additional ventures since Fiscal Year 22/23 Hampa Wellness (a hemp-based product co.) and Peaceful Progress LLP (Cat 1 SEBI approved AIF 20 investments till date). In the past, have built and sold - Winter Logistics to M/s Dubai Port. Management Buy Out (by-self), and Multi Million Dollars PE-funding (Goldman Sachs and Mitsui) of The Good Stuff Private Limited a venture focused on FMCG that has seen Sell Out to M/s DS Group. Mr. Kamal Kumar Agarwal is not related to any director of the company.Upcoming Dividend • Aug 23Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 30 August 2024. Payment date: 06 October 2024. Payout ratio is a comfortable 66% but the company is paying out more than the cash it is generating. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (1.2%).お知らせ • Aug 16Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024, at 16:00 Indian Standard Time.Reported Earnings • Jul 27First quarter 2025 earnings released: EPS: ₹0.75 (vs ₹2.40 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.75 (up from ₹2.40 loss in 1Q 2024). Revenue: ₹753.5m (up 47% from 1Q 2024). Net income: ₹40.3m (up ₹167.9m from 1Q 2024). Profit margin: 5.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.お知らせ • Jul 18Quick Heal Technologies Limited to Report Q1, 2025 Results on Jul 26, 2024Quick Heal Technologies Limited announced that they will report Q1, 2025 results on Jul 26, 2024Reported Earnings • Apr 26Full year 2024 earnings released: EPS: ₹4.56 (vs ₹1.14 in FY 2023)Full year 2024 results: EPS: ₹4.56 (up from ₹1.14 in FY 2023). Revenue: ₹3.13b (up 13% from FY 2023). Net income: ₹242.4m (up 279% from FY 2023). Profit margin: 7.7% (up from 2.3% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.お知らせ • Apr 26Quick Heal Technologies Limited Recommends Final Dividend for the Year 2023-24Quick Heal Technologies Limited has recommended a final dividend of 3 per equity share of 10/- each for the year 2023-24 subject to approval of shareholders in ensuing AGM.お知らせ • Apr 19Quick Heal Technologies Limited to Report Q4, 2024 Results on Apr 25, 2024Quick Heal Technologies Limited announced that they will report Q4, 2024 results at 4:00 PM, Indian Standard Time on Apr 25, 2024Recent Insider Transactions • Mar 12Head of Retail Sales recently sold ₹1.1m worth of stockOn the 4th of March, Deepak Mishra sold around 2k shares on-market at roughly ₹565 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹41m more than they bought in the last 12 months.Recent Insider Transactions • Mar 06Head of Retail Sales recently sold ₹3.5m worth of stockOn the 1st of March, Deepak Mishra sold around 6k shares on-market at roughly ₹545 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹40m more than they bought in the last 12 months.お知らせ • Jan 25Quick Heal Technologies Limited Announces Appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product OfficerQuick Heal Technologies Limited announced the appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product Officer, effective from January 24, 2024. Dr. Lalit is PHD in Computer Science and Bachelor of Engineering from IIT Hyderabad in Threat Intelligence. He has experience of over 25 year in IT and Cyber Security Industry.Reported Earnings • Jan 25Third quarter 2024 earnings released: EPS: ₹1.89 (vs ₹1.70 loss in 3Q 2023)Third quarter 2024 results: EPS: ₹1.89 (up from ₹1.70 loss in 3Q 2023). Revenue: ₹860.7m (up 29% from 3Q 2023). Net income: ₹100.6m (up ₹193.5m from 3Q 2023). Profit margin: 12% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.お知らせ • Jan 11Quick Heal Technologies Limited to Report Q2, 2024 Results on Jan 24, 2024Quick Heal Technologies Limited announced that they will report Q2, 2024 results on Jan 24, 2024Recent Insider Transactions • Dec 20Chief Product Officer recently sold ₹29m worth of stockOn the 15th of December, Sanjay Agrawal sold around 77k shares on-market at roughly ₹369 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Oct 29Second quarter 2024 earnings released: EPS: ₹2.43 (vs ₹3.82 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.43 (down from ₹3.82 in 2Q 2023). Revenue: ₹840.5m (down 17% from 2Q 2023). Net income: ₹129.0m (down 42% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.お知らせ • Oct 28Quick Heal Technologies Limited Appoints Sarang Deshpande as Company Secretary and Compliance OfficerQuick Heal Technologies Limited announced the appointment of Mr. Sarang Deshpande as company Secretary and Compliance Officer. Date of appointment is 26 October, 2023. Mr. Sarang Deshpande is a member of Institute of Company Secretaries of India (ICSI). He is a Bachelor of Legislative Law (LL.B.) and Master of Commerce (M.Com) having more than 18 years of experience in the field of secretarial, legal and compliance of listed and unlisted companies.お知らせ • Sep 13Quick Heal Technologies Limited Announces the Resignation of Vinav Agarwal as Compliance Officer, Effective September 15, 2023Quick Heal Technologies Limited announced the resignation of Mr. Vinav Agarwal as Compliance Officer, due to personal reasons. Date of cessation is September 15, 2023.Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Richard Stiennon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Share price has been volatile over the past 3 months (7.3% average weekly change).お知らせ • Jul 22Quick Heal Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023Quick Heal Technologies Limited at its Annual General Meeting to be held on August 11, 2023, proposed to declare a final dividend of INR 2.50 per equity share of face value INR 10 each for the financial year ended March 31, 2023.New Risk • Jul 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.08b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Market cap is less than US$100m (₹8.08b market cap, or US$98.5m).Reported Earnings • Jul 21First quarter 2024 earnings released: ₹2.40 loss per share (vs ₹0.03 profit in 1Q 2023)First quarter 2024 results: ₹2.40 loss per share (down from ₹0.03 profit in 1Q 2023). Revenue: ₹561.7m (down 8.0% from 1Q 2023). Net loss: ₹127.6m (down ₹129.4m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.お知らせ • Jul 18Quick Heal Technologies Limited Announces Resignation of Srinivasa Rao as Company Secretary & Key Managerial PersonQuick Heal Technologies Limited announced that Mr. A. Srinivasa Rao, has given the resignation from the post of Company Secretary & Key Managerial Person (KMP) of Company vide his resignation letter as received on July 17, 2023 due to personal reasons.お知らせ • Jul 15Quick Heal Technologies Limited to Report Q1, 2024 Results on Jul 20, 2023Quick Heal Technologies Limited announced that they will report Q1, 2024 results on Jul 20, 2023お知らせ • Jul 04+ 1 more updateQuick Heal Technologies Limited Announces Management ChangesQuick Heal Technologies Limited at its board meeting held on July 03, 2023 re- designated Mr. Kailash Katkar as Managing Director with effect from July 03, 2023 and re-designated Mr. Sanjay Katkar, Joint Managing Director & CTO as Joint Managing Director with effect from July 03, 2023.Reported Earnings • Apr 19Full year 2023 earnings released: EPS: ₹1.14 (vs ₹14.01 in FY 2022)Full year 2023 results: EPS: ₹1.14 (down from ₹14.01 in FY 2022). Revenue: ₹3.00b (down 12% from FY 2022). Net income: ₹64.0m (down 92% from FY 2022). Profit margin: 2.1% (down from 24% in FY 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Jan 25Third quarter 2023 earnings released: ₹1.70 loss per share (vs ₹2.47 profit in 3Q 2022)Third quarter 2023 results: ₹1.70 loss per share (down from ₹2.47 profit in 3Q 2022). Revenue: ₹702.7m (down 12% from 3Q 2022). Net loss: ₹92.9m (down 165% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 8% per year.お知らせ • Jan 17Quick Heal Technologies Limited to Report Q3, 2023 Results on Jan 24, 2023Quick Heal Technologies Limited announced that they will report Q3, 2023 results on Jan 24, 2023お知らせ • Nov 26Quick Heal Technologies Limited Announces Resignation of Mehul Savla as Independent DirectorQuick Heal Technologies Limited informed that Mr. Mehul Savla, Independent Director of the Company, has tendered his resignation on November 25, 2022 being the date of receipt of such resignation letter by the company and which is effective from November 25, 2022. Mr. Mehul Savla, in his resignation letter, mentioned the reasons for his resignation is due to increased level of professional commitments at his end and this is impacting his ability to attend and participate in the Board meeting and committee meetings of the Company.Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹3.82 (vs ₹5.39 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.82 (down from ₹5.39 in 2Q 2022). Revenue: ₹1.01b (down 2.7% from 2Q 2022). Net income: ₹221.6m (down 36% from 2Q 2022). Profit margin: 22% (down from 33% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.Buying Opportunity • Sep 21Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₹242, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 3.3%.Recent Insider Transactions • Sep 15Insider recently sold ₹4.4m worth of stockOn the 9th of September, Reetu Raina sold around 20k shares on-market at roughly ₹221 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.Upcoming Dividend • Aug 11Upcoming dividend of ₹4.50 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 26 September 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.6%).お知らせ • Aug 03Quick Heal Technologies Limited, Annual General Meeting, Aug 26, 2022Quick Heal Technologies Limited, Annual General Meeting, Aug 26, 2022, at 15:30 Indian Standard Time. Agenda: To receive, consider and adopt he audited standalone financial statements of the Company for the financial year ended March 31, 2022 and the reports of the Board of Directors and the Auditors thereon; to receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended March 31, 2022 and the report of Auditors thereon; to declare Dividend on equity shares; to consider Appointment of Mr. Sanjay Katkar as a director liable to retire by rotation; to Approval for the Buyback of Equity Shares of the Company; and to consider other matters.お知らせ • Aug 02Quick Heal Technologies Limited Proposes Dividend for Year Ended March 31, 2022Quick Heal Technologies Limited at AGM on to be held on August 26, 2022 proposed to declare a final dividend of INR 4.50 per equity share of face value INR 10 each for the year ended March 31, 2022.お知らせ • Jul 22Quick Heal Technologies Limited (BSE:539678) announces an Equity Buyback for 5,000,000 shares, for INR 1,500 million.Quick Heal Technologies Limited (BSE:539678) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 equity Shares, for INR 1500 million. The shares will be repurchased at a price of INR 300 per share. The share repurchase program is subject to approval of shareholders by way of a special resolution.Reported Earnings • Jul 22First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.97 in 1Q 2022)First quarter 2023 results: EPS: ₹0.03 (down from ₹0.97 in 1Q 2022). Revenue: ₹642.8m (up 17% from 1Q 2022). Net income: ₹1.80m (down 97% from 1Q 2022). Profit margin: 0.3% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹200, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 64% over the past three years.お知らせ • Jul 16Quick Heal Technologies Limited to Report Q1, 2022 Results on Jul 21, 2022Quick Heal Technologies Limited announced that they will report Q1, 2022 results on Jul 21, 2022お知らせ • Jun 12Quick Heal Technologies Limited Announces Senior Management ChangesQuick Heal Technologies Limited announced that Ms. Reetu Raina, Chief Human Resource Officer of the Company, has resigned from the services of the Company on account of personal reasons. The Company had accepted the resignation and placed on record, appreciation for the services rendered by her during her tenure as CHRO of the Company. Further to inform that Mr. Rahul Matta appointed as a Head - HR of the Company w.e.f June 10, 2022. The brief profile of Mr. Rahul Matta as below: He is an alumnus of IIM- Lucknow, over the past 17+ years of experience. He had worked in diversified roles in some industry leading companies like Sterlite, Genpact, Piramal Healhcare, Dr. Reddy's, Mahindra & Mahindra.Recent Insider Transactions • Jun 01Head of Research & Development recently sold ₹2.9m worth of stockOn the 25th of May, Bibhuti Kar sold around 16k shares on-market at roughly ₹179 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹14m more than they bought in the last 12 months.お知らせ • May 08Quick Heal Technologies Limited Recommends Final Dividend for the Year 2021-2022Quick Heal Technologies Limited announced the board has recommended a final dividend of INR 4.5 per equity share of INR 10 each for the year 2021-22.Reported Earnings • May 07Full year 2022 earnings released: EPS: ₹14.01 (vs ₹16.66 in FY 2021)Full year 2022 results: EPS: ₹14.01 (down from ₹16.66 in FY 2021). Revenue: ₹3.61b (up 8.4% from FY 2021). Net income: ₹831.9m (down 22% from FY 2021). Profit margin: 23% (down from 32% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 16Head of Research & Development recently sold ₹1.0m worth of stockOn the 14th of February, Bibhuti Kar sold around 5k shares on-market at roughly ₹203 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.7m. Insiders have been net sellers, collectively disposing of ₹12m more than they bought in the last 12 months.Reported Earnings • Jan 25Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹2.47 (up from ₹2.10 in 3Q 2021). Revenue: ₹832.5m (up 19% from 3Q 2021). Net income: ₹142.9m (up 6.1% from 3Q 2021). Profit margin: 17% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.Recent Insider Transactions • Dec 04Insider recently sold ₹9.7m worth of stockOn the 2nd of December, Nitin Kulkarni sold around 45k shares on-market at roughly ₹217 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.Reported Earnings • Oct 28Second quarter 2022 earnings released: EPS ₹5.39 (vs ₹4.49 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹1.04b (up 23% from 2Q 2021). Net income: ₹346.3m (up 20% from 2Q 2021). Profit margin: 33% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 3% per year.Valuation Update With 7 Day Price Move • Aug 14Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹234, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Software industry in India. Total loss to shareholders of 6.5% over the past three years.Upcoming Dividend • Jul 22Upcoming dividend of ₹4.00 per shareEligible shareholders must have bought the stock before 29 July 2021. Payment date: 05 September 2021. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.8%).Reported Earnings • Jul 14Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.33b (up 16% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 32% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.Recent Insider Transactions • Jun 02Insider recently sold ₹1.6m worth of stockOn the 31st of May, Manish Jain sold around 8k shares on-market at roughly ₹216 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹2.9m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • May 22Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹227, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 18x in the Software industry in India. Total loss to shareholders of 22% over the past three years.お知らせ • May 16Quick Heal Technologies Limited Recommends Final Dividend for the Year 2020-21The Board of Quick Heal Technologies Limited has recommended a final dividend of INR 4 per equity share of INR 10 each for the year 2020-21.Reported Earnings • May 16Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.57b (up 25% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 05New 90-day high: ₹179The company is up 11% from its price of ₹161 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 27% over the same period.Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹179, the stock is trading at a trailing P/E ratio of 15.3x, up from the previous P/E ratio of 13x. This compares to an average P/E of 18x in the Software industry in India. Total return to shareholders over the past three years is a loss of 27%.Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS ₹2.10 (vs ₹2.77 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹698.8m (up 6.3% from 3Q 2020). Net income: ₹134.6m (down 24% from 3Q 2020). Profit margin: 19% (down from 27% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.お知らせ • Jan 14Quick Heal Technologies Limited (BSE:539678) entered into an agreement to acquire an additional unknown minority stake in L7 Defense Ltd. for $2 million.Quick Heal Technologies Limited (BSE:539678) entered into an agreement to acquire an additional unknown minority stake in L7 Defense Ltd. for $2 million on January 14, 2021. Under the terms, Quick Heal Technologies Limited will acquire 2328 ordinary shares of L7 Defense Ltd. The consideration will be paid in cash. L7 Defense Ltd. reported revenue of $0.156 million as of December 31, 2020. The transaction is expected to complete in the 1st week of February 2021.Reported Earnings • Nov 07Second quarter 2021 earnings released: EPS ₹4.49The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹902.4m (down 8.5% from 2Q 2020). Net income: ₹288.4m (down 22% from 2Q 2020). Profit margin: 32% (down from 37% in 2Q 2020). The decrease in margin was driven by lower revenue.お知らせ • Oct 27Quick Heal Technologies Limited Announces Board AppointmentsQuick Heal Technologies Limited appointed Mr. Sanjay Agrawal and Mr. Bibhuti Kar as Chief Product Officer and Head of Research and Development respectively. The expansion of the leadership team reinforces Quick Heal's commitment to accelerate product innovation and drive expansion of next-generation enterprise security solutions under the "Seqrite®" brand. In his role, Sanjay will be responsible for driving the overall product vision and strategy in line with market expectations. While Bibhuti will drive the company's development efforts leading a team of talented engineering professionals and security researchers. Sanjay is an entrepreneurial engineering and product leader with over two decades of experience and proven success in building cybersecurity products for the global markets. He has served many prestigious and high performing roles, including Vice President of Engineering Application and Security at ColorTokens and Director of Engineering at Cisco. Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry. An alumnus of IIT Kharagpur with a master's in ECE, he started his career with the Defense Research and Development Organization (DRDO) as a project assistant on missile communication systems. Post this, he held several prestigious roles in leading technology companies like Cisco, Bell Northern Research and Sophos.Is New 90 Day High Low • Oct 05New 90-day high: ₹171The company is up 47% from its price of ₹116 on 07 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 41% over the same period.お知らせ • Jul 18+ 3 more updatesQuick Heal Technologies Limited to Report Q1, 2021 Results on Aug 14, 2020Quick Heal Technologies Limited announced that they will report Q1, 2021 results on Aug 14, 2020株主還元539678IN SoftwareIN 市場7D-5.3%3.8%-0.2%1Y-31.3%-16.4%0.02%株主還元を見る業界別リターン: 539678過去 1 年間で-16.4 % の収益を上げたIndian Software業界を下回りました。リターン対市場: 539678は、過去 1 年間で0 % のリターンを上げたIndian市場を下回りました。価格変動Is 539678's price volatile compared to industry and market?539678 volatility539678 Average Weekly Movement10.2%Software Industry Average Movement7.6%Market Average Movement7.2%10% most volatile stocks in IN Market10.1%10% least volatile stocks in IN Market4.8%安定した株価: 539678の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 539678の weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト1995973Kailash Katkarwww.quickheal.co.inクイック・ヒール・テクノロジーズ社は、インド国内外の消費者、中小企業、政府機関、企業向けにセキュリティ・ソフトウェア製品とソリューションの提供に従事している。コンシューマー部門、企業・政府部門を通じて事業を展開している。クイック・ヒールのブランドで、トータル・セキュリティ、インターネット・セキュリティ、アンチウイルス・プロ、Mac用セキュリティ、アンドロイド用トータル・セキュリティ、モバイル・セキュリティ、トータル・セキュリティ・マルチデバイス、インターネット・セキュリティ・エッセンシャル、トータル・セキュリティ・フェスティブ・パックなどのウイルス対策ソリューションを提供している。Seqriteブランドでは、エンドポイントプロテクション、エンドポイントプロテクションクラウド、EDR、XDR、MDR、ZTNZ、エンタープライズモビリティ管理、ワークスペース、データプライバシーを提供している。国内販売代理店、一次代理店、ビジネスパートナー、ウェブサイトおよびeコマース向けに製品を販売している。クイック・ヒール・テクノロジーズ・リミテッドは1995年に設立され、インドのプネーに本社を置いている。もっと見るQuick Heal Technologies Limited 基礎のまとめQuick Heal Technologies の収益と売上を時価総額と比較するとどうか。539678 基礎統計学時価総額₹10.73b収益（TTM）₹57.60m売上高(TTM)₹2.77b186.2xPER（株価収益率3.9xP/Sレシオ539678 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計539678 損益計算書（TTM）収益₹2.77b売上原価₹80.60m売上総利益₹2.69bその他の費用₹2.64b収益₹57.60m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）1.06グロス・マージン97.09%純利益率2.08%有利子負債／自己資本比率0%539678 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:24終値2026/05/22 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Quick Heal Technologies Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Kameswari V. S. ChavaliFirstCall ResearchVaibhav DhasmanaJefferies LLC
New Risk • May 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin).
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).
New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).
Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026
Reported Earnings • Oct 19Second quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.77 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.43 (up from ₹0.77 in 2Q 2025). Revenue: ₹879.0m (up 20% from 2Q 2025). Net income: ₹79.1m (up 91% from 2Q 2025). Profit margin: 9.0% (up from 5.6% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
New Risk • May 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin).
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹7.79b market cap, or US$83.5m).
New Risk • Feb 26New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.98b (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 50% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (2.1% net profit margin). Market cap is less than US$100m (₹8.98b market cap, or US$98.7m).
Reported Earnings • Jan 30Third quarter 2026 earnings released: EPS: ₹1.19 (vs ₹0.02 in 3Q 2025)Third quarter 2026 results: EPS: ₹1.19 (up from ₹0.02 in 3Q 2025). Revenue: ₹804.9m (up 14% from 3Q 2025). Net income: ₹66.1m (up ₹65.0m from 3Q 2025). Profit margin: 8.2% (up from 0.2% in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
お知らせ • Jan 22Quick Heal Technologies Limited to Report Q3, 2026 Results on Jan 29, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results at 4:00 PM, Indian Standard Time on Jan 29, 2026
Reported Earnings • Oct 19Second quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.77 in 2Q 2025)Second quarter 2026 results: EPS: ₹1.43 (up from ₹0.77 in 2Q 2025). Revenue: ₹879.0m (up 20% from 2Q 2025). Net income: ₹79.1m (up 91% from 2Q 2025). Profit margin: 9.0% (up from 5.6% in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 19% per year, which means it is well ahead of earnings.
お知らせ • Sep 02+ 2 more updatesQuick Heal Technologies Limited to Report Q3, 2026 Results on Feb 14, 2026Quick Heal Technologies Limited announced that they will report Q3, 2026 results on Feb 14, 2026
お知らせ • Sep 01Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025Quick Heal Technologies Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time.
Reported Earnings • Aug 08First quarter 2026 earnings released: ₹1.00 loss per share (vs ₹0.75 profit in 1Q 2025)First quarter 2026 results: ₹1.00 loss per share (down from ₹0.75 profit in 1Q 2025). Revenue: ₹629.8m (down 10% from 1Q 2025). Net loss: ₹55.1m (down 237% from profit in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
お知らせ • Aug 02Quick Heal Technologies Limited to Report Q1, 2026 Results on Aug 07, 2025Quick Heal Technologies Limited announced that they will report Q1, 2026 results on Aug 07, 2025
New Risk • Jun 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.8% average weekly change). Profit margins are more than 30% lower than last year (1.8% net profit margin).
Reported Earnings • May 10Full year 2025 earnings released: EPS: ₹0.94 (vs ₹4.56 in FY 2024)Full year 2025 results: EPS: ₹0.94 (down from ₹4.56 in FY 2024). Revenue: ₹3.00b (up 2.9% from FY 2024). Net income: ₹50.4m (down 79% from FY 2024). Profit margin: 1.7% (down from 8.3% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
お知らせ • May 01Quick Heal Technologies Limited to Report Q4, 2025 Results on May 06, 2025Quick Heal Technologies Limited announced that they will report Q4, 2025 results on May 06, 2025
お知らせ • Apr 01Quick Heal Technologies Limited Announces Resignation of Shailesh Lakhani as DirectorQuick Heal Technologies Limited announced resignation of Mr. Shailesh Lakhani as Director with effect from 31 March 2025.
Valuation Update With 7 Day Price Move • Feb 28Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹297, the stock trades at a trailing P/E ratio of 71.5x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 74% over the past three years.
Reported Earnings • Feb 05Third quarter 2025 earnings released: EPS: ₹0.02 (vs ₹1.89 in 3Q 2024)Third quarter 2025 results: EPS: ₹0.02 (down from ₹1.89 in 3Q 2024). Revenue: ₹755.2m (down 7.8% from 3Q 2024). Net income: ₹1.10m (down 99% from 3Q 2024). Profit margin: 0.1% (down from 12% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings.
お知らせ • Jan 29Quick Heal Technologies Limited to Report Q3, 2025 Results on Feb 04, 2025Quick Heal Technologies Limited announced that they will report Q3, 2025 results at 12:08 PM, Indian Standard Time on Feb 04, 2025
Valuation Update With 7 Day Price Move • Jan 27Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹469, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 37x in the Software industry in India. Total returns to shareholders of 135% over the past three years.
お知らせ • Dec 04Quick Heal Technologies Limited Launches Seqrite Malware Analysis Platform and Threat Intel SolutionQuick Heal Technologies Limited announced that the company announce the launch of its new product on 4 December, 2024 and issue of India Cyber Threat Report 2025. The product named Seqrite Malware Analysis Platform (SMAP) and Threat Intel Solution is set to launch on 4 December 2024. It falls under the category of Enterprise Security Software, specifically designed as a Malware Analysis Platform and Threat Intel Solution. This product will cater to the domestic market initially, with the first phase being introduced in the Domestic Market and plans to subsequently expand into other geographies.
New Risk • Nov 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹19m sold).
Reported Earnings • Oct 18Second quarter 2025 earnings released: EPS: ₹0.77 (vs ₹2.43 in 2Q 2024)Second quarter 2025 results: EPS: ₹0.77 (down from ₹2.43 in 2Q 2024). Revenue: ₹786.9m (flat on 2Q 2024). Net income: ₹41.5m (down 68% from 2Q 2024). Profit margin: 5.3% (down from 17% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.
お知らせ • Oct 11Quick Heal Technologies Limited to Report Q2, 2025 Results on Oct 17, 2024Quick Heal Technologies Limited announced that they will report Q2, 2025 results on Oct 17, 2024
お知らせ • Oct 04Quick Heal Technologies Limited Announces the Launch of India's First Fraud Prevention Solution - AntiFraud.AIQuick Heal Technologies Limited announced the launch of India's first fraud prevention solution - AntiFraud.AI. This 'Made in India' solution opens a whole new category revolutionizing digital safety against the escalating threat of financial frauds which is impacting everyone including the most tech-savvy. The launch of AntiFraud.AI comes at a crucial time when financial fraud has reached alarming levels. According to the Indian Cybercrime Coordination Centre, the approximate amount that Indians lost to fraudsters between January to April 2024 stood at 1750 crores. The gravity of the situation is further underlined by the National Cybercrime Reporting Portal, suffered losses were reported through over 740,000 complaints. These staggering figures highlight the urgent need for comprehensive fraud prevention solutions, a need that Quick Heal's AntiFraud.AI aims to address head-on. AntiFraud.AI boasts a wide range of robust features designed to enhance user security and safeguard sensitive information. Key Features Include: 1. Risk Profile - Assess risk level with actionable recommendations to reduce exposure to fraud. 2. Fraud Call Alert - Alerts on receiving a potentially fraudulent call. 3. Scam Protection - Employs sophisticated algorithms to identify and block phishing links and fraudulent websites, enhancing online security. 4. Banking Fraud Alert - Utilizes artificial intelligence to detect and alert users to potential banking fraud attempts in real-time. 5. Fraud Protect Buddy - Empowers users to safeguard their loved ones by sharing alerts and security tips, specifically addressing the vulnerabilities of less tech-savvy individuals. 6. Fraud App Detector - Continuously scans for malicious applications and delivers real-time alerts about potentially harmful apps. 7. Secure Payments - Ensures a safe environment for online transactions and monitors for suspicious activity throughout the payment process. Unauthorized Access Alert - Notifies users if their device's microphone or camera is activated without consent, protecting against covert surveillance. Dark Web Monitoring - Actively scans the dark web for compromised sensitive data and provides timely notifications if users' information is found. . Call Forwarding Alert - Alerts when calls are being redirected without consent, The solution also offers Screen share alert, Payee Name Announcer, Spy Alert, File Vault and Browsing Protection and more. In addition to these, The Information Hub feature provides access to in-depth research and fraud intelligence from Seqrite Labs, India's largest malware analysis facility, keeping users informed about evolving threats with the latest fraud trends and prevention tips. This feature allows users to access Quick Heal's extensive domain expertise and knowledge. Furthermore, the Victim Support feature offers step- by-step guidance for those who fall victim to fraud, aiding in recovery and necessary actions. Together, these elements create a robust defense against fraud and enhance overall digital security.
Board Change • Oct 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Kamal Agarwal was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Sep 09Quick Heal Technologies Limited Appoints Kamal Kumar Agarwal as an Independent DirectorQuick Heal Technologies Limited approved the appointment of Mr. Kamal Kumar Agarwal as an Independent Director of the company for a first term of five years commencing from July 26, 2024 at the AGM held on September 06, 2024. Mr. Kamal Kumar Agarwal 43, is a graduate in Bachelor of Commerce in year 2001. He is a Member of the Institute of Chartered Accountants of India. Part of CFO 100 2013 and 2016 Honor list under 'Winning Edge in a Finance Start-up. Mr. Kamal Kumar Agarwal, serving /served as Non-Executive Director & Investor Advisor for M/s NewCold, MN Bio-Technology, Giant Connection & a few. Mr. Kamal Kumar Agarwal has served as Group CFO - Indian Subcontinent & Director at Ferrero India Private Limited. He was also worked with blue chip companies Cadbury India Private Limited, ITC Limited and Tata Teleservices Limited. Currently incubating two additional ventures since Fiscal Year 22/23 Hampa Wellness (a hemp-based product co.) and Peaceful Progress LLP (Cat 1 SEBI approved AIF 20 investments till date). In the past, have built and sold - Winter Logistics to M/s Dubai Port. Management Buy Out (by-self), and Multi Million Dollars PE-funding (Goldman Sachs and Mitsui) of The Good Stuff Private Limited a venture focused on FMCG that has seen Sell Out to M/s DS Group. Mr. Kamal Kumar Agarwal is not related to any director of the company.
Upcoming Dividend • Aug 23Upcoming dividend of ₹3.00 per shareEligible shareholders must have bought the stock before 30 August 2024. Payment date: 06 October 2024. Payout ratio is a comfortable 66% but the company is paying out more than the cash it is generating. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.1%). Lower than average of industry peers (1.2%).
お知らせ • Aug 16Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024Quick Heal Technologies Limited, Annual General Meeting, Sep 06, 2024, at 16:00 Indian Standard Time.
Reported Earnings • Jul 27First quarter 2025 earnings released: EPS: ₹0.75 (vs ₹2.40 loss in 1Q 2024)First quarter 2025 results: EPS: ₹0.75 (up from ₹2.40 loss in 1Q 2024). Revenue: ₹753.5m (up 47% from 1Q 2024). Net income: ₹40.3m (up ₹167.9m from 1Q 2024). Profit margin: 5.3% (up from net loss in 1Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.
お知らせ • Jul 18Quick Heal Technologies Limited to Report Q1, 2025 Results on Jul 26, 2024Quick Heal Technologies Limited announced that they will report Q1, 2025 results on Jul 26, 2024
Reported Earnings • Apr 26Full year 2024 earnings released: EPS: ₹4.56 (vs ₹1.14 in FY 2023)Full year 2024 results: EPS: ₹4.56 (up from ₹1.14 in FY 2023). Revenue: ₹3.13b (up 13% from FY 2023). Net income: ₹242.4m (up 279% from FY 2023). Profit margin: 7.7% (up from 2.3% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 26Quick Heal Technologies Limited Recommends Final Dividend for the Year 2023-24Quick Heal Technologies Limited has recommended a final dividend of 3 per equity share of 10/- each for the year 2023-24 subject to approval of shareholders in ensuing AGM.
お知らせ • Apr 19Quick Heal Technologies Limited to Report Q4, 2024 Results on Apr 25, 2024Quick Heal Technologies Limited announced that they will report Q4, 2024 results at 4:00 PM, Indian Standard Time on Apr 25, 2024
Recent Insider Transactions • Mar 12Head of Retail Sales recently sold ₹1.1m worth of stockOn the 4th of March, Deepak Mishra sold around 2k shares on-market at roughly ₹565 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹41m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 06Head of Retail Sales recently sold ₹3.5m worth of stockOn the 1st of March, Deepak Mishra sold around 6k shares on-market at roughly ₹545 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹29m. Insiders have been net sellers, collectively disposing of ₹40m more than they bought in the last 12 months.
お知らせ • Jan 25Quick Heal Technologies Limited Announces Appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product OfficerQuick Heal Technologies Limited announced the appointment of Dr. Lalit Mohan Sanagavarapu as Chief Product Officer, effective from January 24, 2024. Dr. Lalit is PHD in Computer Science and Bachelor of Engineering from IIT Hyderabad in Threat Intelligence. He has experience of over 25 year in IT and Cyber Security Industry.
Reported Earnings • Jan 25Third quarter 2024 earnings released: EPS: ₹1.89 (vs ₹1.70 loss in 3Q 2023)Third quarter 2024 results: EPS: ₹1.89 (up from ₹1.70 loss in 3Q 2023). Revenue: ₹860.7m (up 29% from 3Q 2023). Net income: ₹100.6m (up ₹193.5m from 3Q 2023). Profit margin: 12% (up from net loss in 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 11Quick Heal Technologies Limited to Report Q2, 2024 Results on Jan 24, 2024Quick Heal Technologies Limited announced that they will report Q2, 2024 results on Jan 24, 2024
Recent Insider Transactions • Dec 20Chief Product Officer recently sold ₹29m worth of stockOn the 15th of December, Sanjay Agrawal sold around 77k shares on-market at roughly ₹369 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Oct 29Second quarter 2024 earnings released: EPS: ₹2.43 (vs ₹3.82 in 2Q 2023)Second quarter 2024 results: EPS: ₹2.43 (down from ₹3.82 in 2Q 2023). Revenue: ₹840.5m (down 17% from 2Q 2023). Net income: ₹129.0m (down 42% from 2Q 2023). Profit margin: 15% (down from 22% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings.
お知らせ • Oct 28Quick Heal Technologies Limited Appoints Sarang Deshpande as Company Secretary and Compliance OfficerQuick Heal Technologies Limited announced the appointment of Mr. Sarang Deshpande as company Secretary and Compliance Officer. Date of appointment is 26 October, 2023. Mr. Sarang Deshpande is a member of Institute of Company Secretaries of India (ICSI). He is a Bachelor of Legislative Law (LL.B.) and Master of Commerce (M.Com) having more than 18 years of experience in the field of secretarial, legal and compliance of listed and unlisted companies.
お知らせ • Sep 13Quick Heal Technologies Limited Announces the Resignation of Vinav Agarwal as Compliance Officer, Effective September 15, 2023Quick Heal Technologies Limited announced the resignation of Mr. Vinav Agarwal as Compliance Officer, due to personal reasons. Date of cessation is September 15, 2023.
Board Change • Sep 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Richard Stiennon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Aug 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Share price has been volatile over the past 3 months (7.3% average weekly change).
お知らせ • Jul 22Quick Heal Technologies Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023Quick Heal Technologies Limited at its Annual General Meeting to be held on August 11, 2023, proposed to declare a final dividend of INR 2.50 per equity share of face value INR 10 each for the financial year ended March 31, 2023.
New Risk • Jul 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₹8.08b (US$98.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risks Dividend is not well covered by earnings (218% payout ratio). Market cap is less than US$100m (₹8.08b market cap, or US$98.5m).
Reported Earnings • Jul 21First quarter 2024 earnings released: ₹2.40 loss per share (vs ₹0.03 profit in 1Q 2023)First quarter 2024 results: ₹2.40 loss per share (down from ₹0.03 profit in 1Q 2023). Revenue: ₹561.7m (down 8.0% from 1Q 2023). Net loss: ₹127.6m (down ₹129.4m from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings.
お知らせ • Jul 18Quick Heal Technologies Limited Announces Resignation of Srinivasa Rao as Company Secretary & Key Managerial PersonQuick Heal Technologies Limited announced that Mr. A. Srinivasa Rao, has given the resignation from the post of Company Secretary & Key Managerial Person (KMP) of Company vide his resignation letter as received on July 17, 2023 due to personal reasons.
お知らせ • Jul 15Quick Heal Technologies Limited to Report Q1, 2024 Results on Jul 20, 2023Quick Heal Technologies Limited announced that they will report Q1, 2024 results on Jul 20, 2023
お知らせ • Jul 04+ 1 more updateQuick Heal Technologies Limited Announces Management ChangesQuick Heal Technologies Limited at its board meeting held on July 03, 2023 re- designated Mr. Kailash Katkar as Managing Director with effect from July 03, 2023 and re-designated Mr. Sanjay Katkar, Joint Managing Director & CTO as Joint Managing Director with effect from July 03, 2023.
Reported Earnings • Apr 19Full year 2023 earnings released: EPS: ₹1.14 (vs ₹14.01 in FY 2022)Full year 2023 results: EPS: ₹1.14 (down from ₹14.01 in FY 2022). Revenue: ₹3.00b (down 12% from FY 2022). Net income: ₹64.0m (down 92% from FY 2022). Profit margin: 2.1% (down from 24% in FY 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Jan 25Third quarter 2023 earnings released: ₹1.70 loss per share (vs ₹2.47 profit in 3Q 2022)Third quarter 2023 results: ₹1.70 loss per share (down from ₹2.47 profit in 3Q 2022). Revenue: ₹702.7m (down 12% from 3Q 2022). Net loss: ₹92.9m (down 165% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 8% per year.
お知らせ • Jan 17Quick Heal Technologies Limited to Report Q3, 2023 Results on Jan 24, 2023Quick Heal Technologies Limited announced that they will report Q3, 2023 results on Jan 24, 2023
お知らせ • Nov 26Quick Heal Technologies Limited Announces Resignation of Mehul Savla as Independent DirectorQuick Heal Technologies Limited informed that Mr. Mehul Savla, Independent Director of the Company, has tendered his resignation on November 25, 2022 being the date of receipt of such resignation letter by the company and which is effective from November 25, 2022. Mr. Mehul Savla, in his resignation letter, mentioned the reasons for his resignation is due to increased level of professional commitments at his end and this is impacting his ability to attend and participate in the Board meeting and committee meetings of the Company.
Reported Earnings • Oct 21Second quarter 2023 earnings released: EPS: ₹3.82 (vs ₹5.39 in 2Q 2022)Second quarter 2023 results: EPS: ₹3.82 (down from ₹5.39 in 2Q 2022). Revenue: ₹1.01b (down 2.7% from 2Q 2022). Net income: ₹221.6m (down 36% from 2Q 2022). Profit margin: 22% (down from 33% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth.
Buying Opportunity • Sep 21Now 21% undervaluedOver the last 90 days, the stock is up 27%. The fair value is estimated to be ₹242, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.8% over the last 3 years. Earnings per share has grown by 3.3%.
Recent Insider Transactions • Sep 15Insider recently sold ₹4.4m worth of stockOn the 9th of September, Reetu Raina sold around 20k shares on-market at roughly ₹221 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.
Upcoming Dividend • Aug 11Upcoming dividend of ₹4.50 per shareEligible shareholders must have bought the stock before 18 August 2022. Payment date: 26 September 2022. Payout ratio is a comfortable 34% and this is well supported by cash flows. Trailing yield: 2.2%. Within top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.6%).
お知らせ • Aug 03Quick Heal Technologies Limited, Annual General Meeting, Aug 26, 2022Quick Heal Technologies Limited, Annual General Meeting, Aug 26, 2022, at 15:30 Indian Standard Time. Agenda: To receive, consider and adopt he audited standalone financial statements of the Company for the financial year ended March 31, 2022 and the reports of the Board of Directors and the Auditors thereon; to receive, consider and adopt the audited consolidated financial statements of the Company for the financial year ended March 31, 2022 and the report of Auditors thereon; to declare Dividend on equity shares; to consider Appointment of Mr. Sanjay Katkar as a director liable to retire by rotation; to Approval for the Buyback of Equity Shares of the Company; and to consider other matters.
お知らせ • Aug 02Quick Heal Technologies Limited Proposes Dividend for Year Ended March 31, 2022Quick Heal Technologies Limited at AGM on to be held on August 26, 2022 proposed to declare a final dividend of INR 4.50 per equity share of face value INR 10 each for the year ended March 31, 2022.
お知らせ • Jul 22Quick Heal Technologies Limited (BSE:539678) announces an Equity Buyback for 5,000,000 shares, for INR 1,500 million.Quick Heal Technologies Limited (BSE:539678) announces a share repurchase program. Under the program, the company will repurchase up to 5,000,000 equity Shares, for INR 1500 million. The shares will be repurchased at a price of INR 300 per share. The share repurchase program is subject to approval of shareholders by way of a special resolution.
Reported Earnings • Jul 22First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.97 in 1Q 2022)First quarter 2023 results: EPS: ₹0.03 (down from ₹0.97 in 1Q 2022). Revenue: ₹642.8m (up 17% from 1Q 2022). Net income: ₹1.80m (down 97% from 1Q 2022). Profit margin: 0.3% (down from 11% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has increased by 17% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Jul 18Investor sentiment improved over the past weekAfter last week's 22% share price gain to ₹200, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 31x in the Software industry in India. Total returns to shareholders of 64% over the past three years.
お知らせ • Jul 16Quick Heal Technologies Limited to Report Q1, 2022 Results on Jul 21, 2022Quick Heal Technologies Limited announced that they will report Q1, 2022 results on Jul 21, 2022
お知らせ • Jun 12Quick Heal Technologies Limited Announces Senior Management ChangesQuick Heal Technologies Limited announced that Ms. Reetu Raina, Chief Human Resource Officer of the Company, has resigned from the services of the Company on account of personal reasons. The Company had accepted the resignation and placed on record, appreciation for the services rendered by her during her tenure as CHRO of the Company. Further to inform that Mr. Rahul Matta appointed as a Head - HR of the Company w.e.f June 10, 2022. The brief profile of Mr. Rahul Matta as below: He is an alumnus of IIM- Lucknow, over the past 17+ years of experience. He had worked in diversified roles in some industry leading companies like Sterlite, Genpact, Piramal Healhcare, Dr. Reddy's, Mahindra & Mahindra.
Recent Insider Transactions • Jun 01Head of Research & Development recently sold ₹2.9m worth of stockOn the 25th of May, Bibhuti Kar sold around 16k shares on-market at roughly ₹179 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹14m more than they bought in the last 12 months.
お知らせ • May 08Quick Heal Technologies Limited Recommends Final Dividend for the Year 2021-2022Quick Heal Technologies Limited announced the board has recommended a final dividend of INR 4.5 per equity share of INR 10 each for the year 2021-22.
Reported Earnings • May 07Full year 2022 earnings released: EPS: ₹14.01 (vs ₹16.66 in FY 2021)Full year 2022 results: EPS: ₹14.01 (down from ₹16.66 in FY 2021). Revenue: ₹3.61b (up 8.4% from FY 2021). Net income: ₹831.9m (down 22% from FY 2021). Profit margin: 23% (down from 32% in FY 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 16Head of Research & Development recently sold ₹1.0m worth of stockOn the 14th of February, Bibhuti Kar sold around 5k shares on-market at roughly ₹203 per share. In the last 3 months, there was an even bigger sale from another insider worth ₹9.7m. Insiders have been net sellers, collectively disposing of ₹12m more than they bought in the last 12 months.
Reported Earnings • Jan 25Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: ₹2.47 (up from ₹2.10 in 3Q 2021). Revenue: ₹832.5m (up 19% from 3Q 2021). Net income: ₹142.9m (up 6.1% from 3Q 2021). Profit margin: 17% (down from 19% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 4% per year.
Recent Insider Transactions • Dec 04Insider recently sold ₹9.7m worth of stockOn the 2nd of December, Nitin Kulkarni sold around 45k shares on-market at roughly ₹217 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.
Reported Earnings • Oct 28Second quarter 2022 earnings released: EPS ₹5.39 (vs ₹4.49 in 2Q 2021)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹1.04b (up 23% from 2Q 2021). Net income: ₹346.3m (up 20% from 2Q 2021). Profit margin: 33% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 3% per year.
Valuation Update With 7 Day Price Move • Aug 14Investor sentiment deteriorated over the past weekAfter last week's 22% share price decline to ₹234, the stock trades at a trailing P/E ratio of 17x. Average trailing P/E is 28x in the Software industry in India. Total loss to shareholders of 6.5% over the past three years.
Upcoming Dividend • Jul 22Upcoming dividend of ₹4.00 per shareEligible shareholders must have bought the stock before 29 July 2021. Payment date: 05 September 2021. Trailing yield: 1.4%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (1.8%).
Reported Earnings • Jul 14Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.33b (up 16% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 32% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 7% per year.
Recent Insider Transactions • Jun 02Insider recently sold ₹1.6m worth of stockOn the 31st of May, Manish Jain sold around 8k shares on-market at roughly ₹216 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹2.9m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • May 22Investor sentiment improved over the past weekAfter last week's 20% share price gain to ₹227, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 18x in the Software industry in India. Total loss to shareholders of 22% over the past three years.
お知らせ • May 16Quick Heal Technologies Limited Recommends Final Dividend for the Year 2020-21The Board of Quick Heal Technologies Limited has recommended a final dividend of INR 4 per equity share of INR 10 each for the year 2020-21.
Reported Earnings • May 16Full year 2021 earnings released: EPS ₹16.66 (vs ₹11.34 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹3.57b (up 25% from FY 2020). Net income: ₹1.07b (up 44% from FY 2020). Profit margin: 30% (up from 26% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 05New 90-day high: ₹179The company is up 11% from its price of ₹161 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Software industry, which is up 27% over the same period.
Valuation Update With 7 Day Price Move • Mar 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to ₹179, the stock is trading at a trailing P/E ratio of 15.3x, up from the previous P/E ratio of 13x. This compares to an average P/E of 18x in the Software industry in India. Total return to shareholders over the past three years is a loss of 27%.
Reported Earnings • Feb 06Third quarter 2021 earnings released: EPS ₹2.10 (vs ₹2.77 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₹698.8m (up 6.3% from 3Q 2020). Net income: ₹134.6m (down 24% from 3Q 2020). Profit margin: 19% (down from 27% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings.
お知らせ • Jan 14Quick Heal Technologies Limited (BSE:539678) entered into an agreement to acquire an additional unknown minority stake in L7 Defense Ltd. for $2 million.Quick Heal Technologies Limited (BSE:539678) entered into an agreement to acquire an additional unknown minority stake in L7 Defense Ltd. for $2 million on January 14, 2021. Under the terms, Quick Heal Technologies Limited will acquire 2328 ordinary shares of L7 Defense Ltd. The consideration will be paid in cash. L7 Defense Ltd. reported revenue of $0.156 million as of December 31, 2020. The transaction is expected to complete in the 1st week of February 2021.
Reported Earnings • Nov 07Second quarter 2021 earnings released: EPS ₹4.49The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ₹902.4m (down 8.5% from 2Q 2020). Net income: ₹288.4m (down 22% from 2Q 2020). Profit margin: 32% (down from 37% in 2Q 2020). The decrease in margin was driven by lower revenue.
お知らせ • Oct 27Quick Heal Technologies Limited Announces Board AppointmentsQuick Heal Technologies Limited appointed Mr. Sanjay Agrawal and Mr. Bibhuti Kar as Chief Product Officer and Head of Research and Development respectively. The expansion of the leadership team reinforces Quick Heal's commitment to accelerate product innovation and drive expansion of next-generation enterprise security solutions under the "Seqrite®" brand. In his role, Sanjay will be responsible for driving the overall product vision and strategy in line with market expectations. While Bibhuti will drive the company's development efforts leading a team of talented engineering professionals and security researchers. Sanjay is an entrepreneurial engineering and product leader with over two decades of experience and proven success in building cybersecurity products for the global markets. He has served many prestigious and high performing roles, including Vice President of Engineering Application and Security at ColorTokens and Director of Engineering at Cisco. Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry. An alumnus of IIT Kharagpur with a master's in ECE, he started his career with the Defense Research and Development Organization (DRDO) as a project assistant on missile communication systems. Post this, he held several prestigious roles in leading technology companies like Cisco, Bell Northern Research and Sophos.
Is New 90 Day High Low • Oct 05New 90-day high: ₹171The company is up 47% from its price of ₹116 on 07 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Software industry, which is up 41% over the same period.
お知らせ • Jul 18+ 3 more updatesQuick Heal Technologies Limited to Report Q1, 2021 Results on Aug 14, 2020Quick Heal Technologies Limited announced that they will report Q1, 2021 results on Aug 14, 2020
